Abstract
Utilising biomarkers for COVID-19 diagnosis, prediction of treatment response and overall prognostication have been investigated recently. However, these ventures have only considered the use of blood-based molecular markers. Saliva is another biofluid that warrants being applied in similar fashion with major advantages that centres on its non-invasive and repeatable collection as well as cost-efficiency. To this end, this article presents a hypothesis for the sources of biomarkers useful clinically for COVID-19 disease outcome estimation and identify the likely implications of their detection in saliva.
Keywords:
COVID-19 pandemic; SARS-CoV-2; Saliva biomarkers.
Copyright © 2020 Elsevier Ltd. All rights reserved.
MeSH terms
-
Betacoronavirus*
-
Biomarkers / analysis*
-
Biomarkers / blood
-
COVID-19
-
Coronavirus Infections / diagnosis
-
Coronavirus Infections / immunology
-
Coronavirus Infections / metabolism*
-
Coronavirus Infections / therapy
-
Cytokines / analysis
-
Diagnostic Tests, Routine
-
Extracellular Vesicles
-
Gingival Crevicular Fluid / chemistry
-
Humans
-
MicroRNAs / analysis
-
Models, Immunological*
-
Mouth Diseases / complications
-
Mouth Diseases / metabolism
-
Pandemics*
-
Pneumonia, Viral / diagnosis
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / metabolism*
-
Pneumonia, Viral / therapy
-
SARS-CoV-2
-
Saliva / chemistry*
-
Saliva / immunology
-
Saliva / virology
-
Salivary Glands / metabolism
-
Salivary Glands / virology
-
Salivary Proteins and Peptides / analysis
Substances
-
Biomarkers
-
Cytokines
-
MicroRNAs
-
Salivary Proteins and Peptides